– CANADA, Toronto – Kalytera Therapeutics, Inc. (TSX: KLY | OTCQB: KALTF), today announced that Rob Hutchison has joined the Board to fill the vacancy created by the resignation of Gary Leong, an independent director who also served on the Company’s Audit and Governance and Nominating Committees. Mr. Hutchison, who is an independent director, will also serve as a member of the Company’s Audit, Compensation and Governance, and Nominating Committees.
“Rob brings a wealth of financial and business experience to Kalytera,” commented Ron Erickson, Chairman of the Board. “Rob has significant expertise regarding intellectual property, patents, business valuations, and business management. We are very pleased that he has agreed to join our Board, and we look forward to his contributions as we continue to execute on our strategy in the years to come.”
Mr. Erickson also stated that “Gary Leong has made invaluable contributions to Kalytera during his tenure. On behalf of the Company, we are grateful for his service and dedication.”
Robert Farrell, Kalytera’s President, and CEO stated that “Mr. Hutchison brings extensive financial and business experience to Kalytera, and we welcome him to the Board.” Mr. Farrell went on to say, “I would like to thank Gary Leong for his dedication to the Company, and for the good judgment and guidance that he provided to the Company during his tenure on the Board.”
About Rob Hutchison
Mr. Hutchison currently serves as President, CEO and Chairman of RMR Science Technologies, Inc., a Canadian Capital Pool Company listed on the TSX Venture Exchange. In 2007 Rob founded biOasis Technologies and served as President, CEO and Executive Chairman of biOasis through December 2017. From 2013 – 2015 Mr. Hutchison also served as Executive Chairman of Biommune Technologies, a company he formed to acquire certain biotechnology assets from the University of British Columbia.
About Kalytera Therapeutics
Kalytera Therapeutics, Inc. is pioneering the development of the next generation of cannabinoid therapeutics. Through its proven leadership, drug development expertise, and intellectual property portfolio, Kalytera seeks to establish a leading position in the development of novel cannabinoid medicines for a range of important unmet medical needs, with an initial focus on graft versus host disease and the treatment of acute and chronic pain.
For more information: https://kalytera.co
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.